Develops therapeutic and diagnostic products based on its predictive discovery platforms for immune-oncology and other diseases.
Compugen Ltd., a clinical-stage company specializing in therapeutic discovery and development, conducts extensive research and commercializes innovative product candidates across Israel, the United States, and Europe.
Focused on immuno-oncology, Compugen's robust pipeline features several promising candidates. These include COM701, an anti-PVRIG antibody currently undergoing Phase I clinical trials for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT also in Phase I clinical trials for advanced malignancies; and Bapotulimab, targeting ILDR2, progressing through Phase I clinical studies for solid tumors. Additionally, AZD2936, an innovative anti-TIGIT/PD-1 bispecific antibody, is advancing through Phase I/II clinical trials for metastatic non-small cell lung cancer. The company's early-stage programs primarily target myeloid checkpoints, further expanding its therapeutic potential in oncology.
Compugen has established strategic collaborations with leading entities such as Bayer Pharma AG and Bristol-Myers Squibb to advance antibody-based therapeutics and combination therapies for immune checkpoint regulators. The company also collaborates with Johns Hopkins School of Medicine to explore novel T cell and myeloid checkpoint targets, underscoring its commitment to pioneering immunotherapy solutions. Founded in 1993 and headquartered in Holon, Israel, Compugen Ltd. continues to drive innovation in the biopharmaceutical industry with a focus on advancing novel therapies to address critical unmet medical needs globally.